Drug Profile
Research programme: CNS disorder therapies - NEUWAY Pharma
Latest Information Update: 13 Sep 2022
Price :
$50
*
At a glance
- Originator NEUWAY Pharma
- Class Antivirals; Gene therapies; Neuroprotectants
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research CNS disorders
- No development reported Huntington's disease; Metachromatic leukodystrophy; Progressive multifocal leukoencephalopathy
Most Recent Events
- 09 Sep 2022 Early research development for CNS-disorders is ongoing in germany
- 28 Aug 2022 No recent reports of development identified for research development in Huntington's-disease in Germany
- 28 Aug 2022 No recent reports of development identified for research development in Metachromatic leukodystrophy in Germany